Eton Pharmaceuticals, Inc. (ETON) News
Filter ETON News Items
ETON News Results
|Loading, please wait...|
ETON News Highlights
- 500 - Internal server error
- Over the past 22 days, the trend for ETON's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- CRL, BIO and HROW are the most mentioned tickers in articles about ETON.
Latest ETON News From Around the Web
Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.
Eton Pharmaceuticals Inc (NASDAQ: ETON) has acquired the U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector. The product is under development as a rescue treatment for adrenal crisis. Zeneo is a pre-filled, single-use device that propels medication through the skin in less than a tenth of a second. Crossject holds more than 400 global patents on the device, including 24 issued in the U.S. extending as far as 2037. Eton expects to submit a marketing application f
Oakozhan/iStock via Getty Images Eton Pharmaceuticals ([[ETON]] -3.2%) announced that the FDA has approved its ephedrine hydrochloride injection, Rezipres for the treatment of clinically important hypotension detected in anesthesia settings. The trading of Eton shares remains halted. “We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use...
Expands Eton’s Adrenal Insufficiency Orphan Drug PortfolioZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency HydrocortisoneProprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037 DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced
DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia. “We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelli
Eton Pharmaceuticals, Inc. (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Eton Pharmaceuticals (ETON) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) related to a dehydrated alcohol injection for treating methanol poisoning. After reviewing the NDA, the FDA has declined to approve it in its present form. Eton shares fell about 16.8% to close at $7.06 on May 28. Amid COVID-19 associated travel restrictions, a pre-approval inspection of the drug’s contract manufacturer in Europe is yet to be completed. According to Eton, the remaining queries raised by the FDA in the CRL will be addressed in the coming months. (See Eton Pharmaceuticals stock analysis on TipRanks) Recently, H.C.
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes. New molecular entity approvals totaled five during the month. NMEs are drugs with active moieties or ingredients that have never been approved by the FDA previously, and are therefore indicators of drug innovation. NME approvals for the month, included Apellis Pharmaceuticals, Inc.'s (NASDAQ: APLS ) Empaveli, indicated for the treatment of paroxysmal nocturnal hemoglobinuria, Johnson & Johnson's (NYSE: JNJ ) Rybrevant for a subtype of non-small cell lung cancer, Lantheus Holdings, Inc.'s (NASDAQ: LNTH ) Pylarify, a fluorinated PSMA-targeted PET imaging agent for detecting prostate cancer, Amgen, Inc.'s K...
Eton Pharmaceuticals (ETON) received a Complete Response Letter (CRL) from the U.S. The post FDA Refuses Approval for Etons New Methanol Poisoning Drug Treatment appeared first on Smarter Analyst .
Photo by robertsrob/iStock via Getty Images Harrow Health Inc. (HROW) had a tough time last year as many of their eyecare focused business customers were closed due to the pandemic or had fewer patients. Fortunately, business is now booming. HROW reported a blowout earnings report for Q1 2021 and has...
Eton Pharmaceuticals Stock Tumbles After FDA Rejects its Dehydrated Alcohol Injection Application For Methanol Poisoning
Eton Pharmaceuticals Inc (NASDAQ: ETON ) has received a Complete Response Letter (CRL) from the FDA related to a marketing application for its dehydrated alcohol injection to treat methanol poisoning. The … Full story available on Benzinga.com